ASCO 2026: Yale Cancer Center's Roy Herbst, recognized as one of the foremost leaders in lung and head & neck cancer research, shares his take on what's in focus at this year's ASCO Annual Meeting
- May 29
- 1 min read
He comments on the progress of PD-1 x VEGF, a closely watched RET inhibitor, and how the field is doing in head & neck cancer lately. Plus, the presentation that everyone is waiting for in pancreatic cancer.
.png){kind=logo}